BofA raises Vaxcyte stock price target to $146 on OPUS-1 data
BofA Securities raised its price target on Vaxcyte (PCVX) to $146 from $130, maintaining a Buy rating. The stock is currently trading at $73.82. The move follows positive OPUS-1 trial results, which met primary endpoints and showed strong performance against competitors. Analysts have revised earnings upwards, but some suggest the stock may be overvalued. Vaxcyte also announced new executive appointments and adjusted its VAX-31 launch timeline to 2029.
How this was made
The 30-second read
Why it matters
The trial success and analyst target raise suggest a significant upside catalyst for Vaxcyte, potentially driving further price appreciation.
Market read
New clinical data and upgraded price target provide a fresh, material catalyst for Vaxcyte, making the news highly relevant for traders.
What to watch
The revised launch timeline to 2029 may temper near‑term upside.
Background
The article reports BofA's new price target and details of Vaxcyte's OPUS-1 Phase 3 trial results, including endpoint achievements and executive appointments.
Ticker impact
BofA raised its price target on Vaxcyte to $146 after the OPUS-1 Phase 3 trial met its primary endpoint and achieved all co-primary endpoints.
likely upward pressure as investors price in higher target and potential market approval.
Analyst target increase and 30% stock surge indicate strong market reaction to new efficacy data.
Market effects
Positive biotech trial results may boost sentiment in the vaccine and infectious disease sector.
U.S. biotech market may see increased buying interest.
Potential impact on global vaccine competition landscape.
Counterpoint
If regulatory review delays or pricing concerns arise, the stock could face volatility despite trial success.
Key entities
- CompanyVaxcyte
Biotech firm developing the VAX-31 vaccine.
- AnalystBofA Securities
Raised price target to $146 based on trial data.
